-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Development of Multivalent Cell Therapies for Treatment of Hematologic Malignancies

Program: Special-Interest Sessions
Session: Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology
Saturday, December 7, 2024, 6:00 PM-9:00 PM

Quenton Bubb, MPhil

Leland Stanford Junior University, Stanford, CA

Disclosures: No relevant conflicts of interest to declare.

See more of: Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>